Drug Trial Radar · NCT06941870
Efanesoctocog Alfa Prophylaxis in Patients With Hemophilia A With Synovial Hypertrophy
Last checked: Nov 19, 2026Latest source record: Nov 9, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
35
Planned (sponsor's estimate)
Start
Sep 23, 2025
Primary completion
Oct 25, 2027
Study completion Oct 25, 2027
Sponsor
- Lead sponsor
- SanofiSanofi (SNY)
- Sponsor type
- Industry
- First posted
- Apr 24, 2025
Design
- Study type
- Interventional
- Phase
- Phase 4
- Allocation
- Non randomized
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 12 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The objective of the study is to assess the improvement of synovial hypertrophy during the 12 months of efanesoctocog alfa prophylaxis once per week (QW) in joints with existing evidence of synovial hypertrophy in participants with hemophilia A. The study duration for each participant is approximately 12 months.
Conditions
- Factor VIII Deficiency
Interventions
Efanesoctocog alfaDrug
Pharmaceutical form:Lyophilized powder in a sterile vial that requires reconstitution with sterile water for injection (diluent)-Route of administration:Intravenous
Primary outcomes
What the sponsor says the trial is designed to measure.
- Proportion of joints with improvement in the Hemophilia Early Arthropathy Detection with Ultrasound (HEAD-US) synovitis domain scoreTime frame: From Baseline up to Week 52
Locations
19 sites in 5 countries. Site status is shown where the registry gives one.
Orthopedic Institute for Children- Site Number : 8400009
Los Angeles, California · Completed
University of California Davis Medical Center-Site Number: 8400005
Sacramento, California · Recruiting
Indiana Hemophilia and Thrombosis Center- Site Number : 8400006
Indianapolis, Indiana · Recruiting
University of Iowa- Site Number : 8400004
Iowa City, Iowa · Recruiting
The Ohio State University Wexner Medical Center - CarePoint East- Site Number : 8400001
Columbus, Ohio · Completed
Oregon Health and Science University-Site Number: 8400002
Portland, Oregon · Recruiting
Washington Center for Bleeding Disorders- Site Number : 8400008
Seattle, Washington · Recruiting
Investigational Site Number : 0360001
Murdoch, Western Australia, Australia · Completed
Investigational Site Number : 1240002
Calgary, Alberta, Canada · Recruiting
Investigational Site Number : 1240001
St. John's, Newfoundland and Labrador, Canada · Recruiting
Investigational Site Number : 1240003
Hamilton, Ontario, Canada · Recruiting
Investigational Site Number : 1240004
Hamilton, Ontario, Canada · Completed
Investigational Site Number : 3920002
Hiroshima, Japan · Completed
Investigational Site Number : 3920001
Saitama, Japan · Recruiting
Investigational Site Number : 3920004
Tokyo, Japan · Completed
Investigational Site Number : 3920003
Kawasaki, Kanagawa, Japan · Recruiting
Investigational Site Number: 1580003
Kaohsiung City, Taiwan · Recruiting
Investigational Site Number: 1580001
Taichung, Taiwan · Recruiting
Investigational Site Number: 1580002
Taipei, Taiwan · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.